Research ArticleClinical Investigations
Dose–Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT
Roel Wierts, Boudewijn Brans, Bas Havekes, Gerrit J. Kemerink, Servais G. Halders, Nicolaas N. Schaper, Walter H. Backes, Felix M. Mottaghy and Walter Jentzen
Journal of Nuclear Medicine July 2016, 57 (7) 1027-1032; DOI: https://doi.org/10.2967/jnumed.115.168799
Roel Wierts
1Maastricht University Medical Center, Maastricht, The Netherlands
Boudewijn Brans
1Maastricht University Medical Center, Maastricht, The Netherlands
Bas Havekes
1Maastricht University Medical Center, Maastricht, The Netherlands
Gerrit J. Kemerink
1Maastricht University Medical Center, Maastricht, The Netherlands
Servais G. Halders
1Maastricht University Medical Center, Maastricht, The Netherlands
Nicolaas N. Schaper
1Maastricht University Medical Center, Maastricht, The Netherlands
Walter H. Backes
1Maastricht University Medical Center, Maastricht, The Netherlands
Felix M. Mottaghy
1Maastricht University Medical Center, Maastricht, The Netherlands
2University Hospital RWTH Aachen University, Aachen, Germany; and
Walter Jentzen
3Klinik für Nuklearmedizin, Universität Duisburg-Essen, Essen, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 7
July 1, 2016
Dose–Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT
Roel Wierts, Boudewijn Brans, Bas Havekes, Gerrit J. Kemerink, Servais G. Halders, Nicolaas N. Schaper, Walter H. Backes, Felix M. Mottaghy, Walter Jentzen
Journal of Nuclear Medicine Jul 2016, 57 (7) 1027-1032; DOI: 10.2967/jnumed.115.168799
Dose–Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT
Roel Wierts, Boudewijn Brans, Bas Havekes, Gerrit J. Kemerink, Servais G. Halders, Nicolaas N. Schaper, Walter H. Backes, Felix M. Mottaghy, Walter Jentzen
Journal of Nuclear Medicine Jul 2016, 57 (7) 1027-1032; DOI: 10.2967/jnumed.115.168799
Jump to section
Related Articles
Cited By...
- Efficacy and Safety of 124I-MIBG Dosimetry-Guided High-Activity 131I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
- Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer
- The Relevance of Dosimetry in Precision Medicine
- Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
- Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer
- THYROPET Study: Is It Biology or Technology That Is the Issue?